3T Head-Only MRI System Gets FDA Clearance
The Signa Magnus MRI device offers a slew rate and gradient amplitude that are reportedly superior to those of 60 or 70 cm bore whole-body MRI systems.
The Food and Drug Administration (FDA) has granted 510(k) clearance for the Signa Magnus system, a 3T magnetic resonance imaging (MRI) system for head-only scanning.
Featuring HyperG gradient technology, the Signa Magnus system facilitates faster MRI scanning with performance levels of 300 mT/m and 750 T/m/s, according to GE HealthCare, the manufacturer of the system. In addition to shorter scan times, the company said the neuroimaging system offers advanced diffusion imaging capabilities and a high signal-to-noise ratio (SNR).
GE HealthCare said the head-only emphasis of the newly FDA-cleared Signa Magnus 3T MRI system facilitates a gradient amplitude and slew rate that exceed those of conventional whole-body MRI platforms. (Image courtesy of GE HealthCare.)
Noting an asymmetrical design that shifts the gradient isocenter to the patient edge of the coil, GE HealthCare said the head-only emphasis of the system facilitates a gradient amplitude and slew rate that exceed those of conventional whole-body MRI platforms.
“We're very excited about the capabilities Signa Magnus provides,” said Kawin Setsompop, Ph.D., an associate professor of radiology at Stanford University. “I plan to leverage the gradient performance to look at microstructures with diffusion imaging, such as axonal diameter. Additionally, using the high slew rate for efficient readout in terms of EPI and spiral to sample k-space faster will help achieve higher resolution with fewer artifacts.”
FDA Clears Virtually Helium-Free 1.5T MRI System from Siemens Healthineers
June 26th 2025Offering a cost- and resource-saving DryCool magnet technology, the Magnetom Flow.Ace MRI system reportedly requires 0.7 liters of liquid helium for cooling over the lifetime of the device in contrast to over 1,000 liters commonly utilized with conventional MRI platforms.
Multinational Study Reaffirms Value of Adjunctive AI for Prostate MRI
June 16th 2025The use of adjunctive AI in biparametric prostate MRI exams led to 3.3 percent and 3.4 percent increases in the AUC and specificity, respectively, for clinically significant prostate cancer (csPCa) in a 360-person cohort drawn from 53 facilities.
Study: AI-Generated ADC Maps from MRI More Than Double Specificity in Prostate Cancer Detection
June 5th 2025Emerging research showed that AI-generated ADC mapping from MRI led to significant increases in accuracy, PPV and specificity in comparison to conventional ADC mapping while achieving a 93 percent sensitivity for PCa.
